TCHP is a combination of chemotherapy and targeted therapy drugs used to treat early-stage HER2-positive breast cancer. It includes docetaxel (Taxotere), carboplatin (Paraplatin), trastuzumab (Herceptin), and pertuzumab (Perjeta). It is used in neoadjuvant (before surgery) and adjuvant (after surgery) settings to shrink tumors and reduce recurrence.

What Does TCHP Stand For?

TCHP stands for the four drugs used in this regimen:

• T – Taxotere (docetaxel)
• C – Carboplatin (Paraplatin)
• H – Herceptin (trastuzumab)
• P – Perjeta (pertuzumab)

This combination is designed to attack cancer cells through multiple mechanisms, enhancing the effectiveness of treatment for HER2-positive breast cancer. Taxotere and carboplatin are chemotherapy drugs, and work to prevent cancer cells from growing and dividing. They also induce cell death. Herceptin and Perjeta are targeted therapies. They attach to a protein on cancer cells called HER2, which blocks growth signals.

When Is TCHP Used in Breast Cancer Treatment?

TCHP is used primarily for HER2-positive, early-stage or node-positive breast cancer. It may also be used for triple-positive patients (ER+/PR+/HER2+). Initial treatments may be followed by maintenance trastuzumab (± endocrine therapy).

TCHP chemotherapy is typically given as neoadjuvant therapy, meaning it is administered before surgery to shrink tumors and improve surgical outcomes. It can also be continued after surgery to eliminate any remaining cancer cells.

How Is TCHP Administered?

TCHP treatment is delivered intravenously in cycles, usually every 21 days (three weeks), for a total of six cycles over approximately 18 weeks. Each drug is infused over a specific duration, with doses carefully scheduled to maximize efficacy and minimize side effects:

• Docetaxel: 60 minutes
• Carboplatin: 30 minutes
• Trastuzumab: 90 minutes for Cycle 1, then over 30-90 minutes for all later cycles
• Pertuzumab: 60 minutes for Cycle 1, and over 30 minutes for all later cycles

After completing the six cycles, patients often continue with maintenance therapy using trastuzumab (Herceptin) and sometimes pertuzumab for up to one year to sustain treatment benefits.

This regimen is typically administered in hospitals or cancer treatment centers. To reduce the risk of infusion reactions and fluid retention, some patients may be prescribed premedication (e.g., acetaminophen, diphenhydramine, and a corticosteroid). Monitoring during the infusion is essential due to potential cardiac and infusion-related reactions.

How Effective Is TCHP?

TCHP chemotherapy has shown significant effectiveness in treating early-stage HER2+ breast cancer. Its effectiveness is measured primarily by the rate of pathologic complete response (pCR)-the absence of detectable cancer in tissue samples after neoadjuvant (pre-surgery) chemotherapy-and by long-term survival outcomes. Studies report high rates of pathologic complete response (pCR) in neoadjuvant settings, often exceeding 50–60%. This indicates that the cancer responds well to this regimen.

• In a phase II clinical trial in patients with HER2+ early breast cancer, the 3-year Kaplan-Meier survival estimate for disease-free survival (DFS) was around 90%.
• Another study of 447 patients reported a 64% pCR rate and around a 90% 3-year DFS rate.
• A phase III randomized, open-label trial (KRISTINE) reported a pCR rate of around 56%.
• Real-world data suggest a 3-year event-free survival rate of around 60% for patients treated with TCHP.

Individual responses to TCHP can vary significantly, depending on patient and disease characteristics.

Related questions

• How soon will my hair grow back after chemotherapy?
• Will I lose my hair during chemotherapy treatment?
• What is the TC chemo regimen and how does it treat breast cancer?

What Are Common Side Effects of TCHP?

TCHP chemotherapy is associated with a broad spectrum of side effects, both short- and long-term. Most patients will experience a combination of these, but the severity and duration vary individually. Common side effects of TCHP include:

• Hair loss
• Fatigue
• Numbness or tingling in the hands or feet
• Mouth sores
• Diarrhea
• Nausea
• Nail changes
• Fluid retention
• Constipation
• Headache
• Rash
• Abnormal blood cell counts
• Infusion reactions
• Heart problems
• Kidney damage
• Changes in hearing
• Changes in menstrual cycle

Routine lab work is recommended to monitor for low blood cell counts. Some patients may experience febrile neutropenia, which may require G-CSF (a type of growth factor that stimulates the bone marrow to produce white blood cells). Cardiac monitoring is also needed due to trastuzumab and pertuzumab, which can cause new or worsening heart failure.

Important Considerations During TCHP Treatment

Due to the potential side effects of TCHP treatment, several important considerations can help you manage treatment safely and effectively.To help monitor for side effects, your healthcare provider will order several tests before and during TCHP treatment.

Cardiac Monitoring

Before starting treatment, an echocardiogram or MUGA scan is recommended to get baseline information about your heart. Your healthcare provider will continue to monitor your heart through these tests every 3 months during treatment, upon completion, and every 6 months for at least 2 years following completion. Depending on your results, you may need more frequent monitoring.

Other Blood Work

Other lab tests you will need to have done include CBC, renal, and liver function tests before each cycle. Your healthcare provider will order blood tests regularly, including before, during, and after treatment.

Pregnancy, Breastfeeding, and Fertility Precautions

Medications in this regimen may cause harm to babies, so it is not recommended for people who are pregnant or breastfeeding. Talk to your healthcare provider about effective contraception while taking TCHP chemotherapy.

TCHP chemotherapy can make it harder to become pregnant. This is because chemotherapy can temporarily or permanently stop menstruation, as well as destroy ovarian follicles. Discuss fertility preservation prior to starting therapy.

Managing side effects

It can help to manage side effects proactively with antiemetics and supportive care. Dietary adjustments, rest, and symptom tracking can help manage some side effects. Getting your lab tests done on time can help your healthcare provider identify certain side effects and treat them accordingly.

Some strategies to help manage side effects include:

• Wash your hands often to prevent infections
• Avoid spicy foods to help with diarrhea and mouth sores
• Balance rest with light physical activity as tolerated to maintain strength and reduce fatigue
• Raise your legs to help with swelling in your ankles
• Use gentle shampoos and soft hair brushes
• Drink plenty of fluids, unless you are fluid-restricted
• Protect your skin from sunlight

Summary

TCHP chemotherapy is a potent, multi-drug regimen combining chemotherapy and targeted therapies to treat HER2-positive breast cancer. Administered intravenously in cycles over several months, it aims to shrink tumors pre-surgery and prevent cancer recurrence post-surgery. Its combination of docetaxel, carboplatin, trastuzumab, and pertuzumab targets cancer cells through different pathways, improving patient outcomes while requiring careful management of side effects and long-term health monitoring.

References

1. Carboplatin [package insert]. Updated July 2021. Fresenius Kabi USA, LLC. Accessed on May 8, 2025 at https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b4fa7aac-c9d2-4af4-a281-3e6cfc502ff6
2. DePolo, J., et. al. What Is Triple-Positive Breast Cancer? Accessed on May 8, 2025 at https://www.breastcancer.org/types/triple-positive
3. Drugs.com. 2025. Tchp Chemo Regimen. Accessed May 8, 2025 at https://www.drugs.com/cg/tchp-chemo-regimen.html
4. EviQ. Updated 2023. Patient information - Breast cancer neoadjuvant - TCHP (docetaxel, carboplatin, trastuzumab and pertuzumab). Accessed May 9, 2025 at https://www.eviq.org.au/medical-oncology/breast/neoadjuvant-adjuvant/3736-breast-neoadjuvant-tchp-docetaxel-carboplat/patient-information#side-effects
5. Fox, K. TCHP Chemo Treatment: Taxotere + Carboplatin + Herceptin + Perjeta. Accessed on May 8, 2025 at https://www.breastcancer.org/drugs/TCHP-chemo
6. Giordano, S. H., et. al. 2022. Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: ASCO Guideline Update. In: Journal of Clinical Oncology. DOI: https://doi.org/10.1200/JCO.22.00519
7. Greenblatt, K., et. al. Updated 2024. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Accessed on May 8, 2025 at https://www.ncbi.nlm.nih.gov/books/NBK532246/
8. Haley, E., et. al. 2025. How Long Does Maintenance Therapy Last for HER2-Positive Breast Cancer? Accessed on May 8, 2025 at https://www.mybcteam.com/resources/how-long-does-maintenance-therapy-last-for-her2-positive-breast-cancer
9. Herceptin [package insert]. Updated 2024. Genentech, Inc. Accessed May 8, 2025 at https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=492dbdb2-077e-4064-bff3-372d6af0a7a2
10. Hurvitz, S. A., et. al. (2018). Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. The Lancet. Oncology, 19(1), 115–126. https://doi.org/10.1016/S1470-2045(17)30716-7
11. Janni, W., et. al. 2008. Node-positive Breast Cancer: Which Are the Best Chemotherapy Regimens?. Breast care (Basel, Switzerland), 3(4), 244–250. https://doi.org/10.1159/000149099
12. Kim, J. Y., et. al. 2022. Real World Evidence of Neoadjuvant Docetaxel/Carboplatin/Trastuzumab/Pertuzumab (TCHP) in Patients with HER2-Positive Early or Locally Advanced Breast Cancer: A Single-Institutional Clinical Experience. Cancer research and treatment, 54(4), 1091–1098. https://doi.org/10.4143/crt.2021.901
13. National Cancer Institute. NCI Dictionary of Cancer Terms: Pathologic Complete Response. Accessed on May 9, 2025 at https://www.cancer.gov/publications/dictionaries/cancer-terms/def/pathologic-complete-response
14. Perjeta [package insert]. Updated April 2025. Genentech, Inc. Accessed on May 8, 2025 at https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=17f85d17-ab71-4f5b-9fe3-0b8c822f69ff
15. Schneeweiss, A., et. al. 2013. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Annals of oncology : official journal of the European Society for Medical Oncology, 24(9), 2278–2284. https://doi.org/10.1093/annonc/mdt182
16. Schneeweiss, A., et. al. 2018. Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer. European journal of cancer (Oxford, England : 1990), 89, 27–35. https://doi.org/10.1016/j.ejca.2017.10.021
17. Trivers, K. F., et. al. 2014. Estimates of young breast cancer survivors at risk for infertility in the U.S. The oncologist, 19(8), 814–822. https://doi.org/10.1634/theoncologist.2014-0016
18. Zhukova, L., et. al. 2023. INSIGHT-HER2BC: Real-world evidence of TCHP regimen to describe the best patient profile and open up questions—The interim results. In: Journal of Clinical Oncology. DOI: https://doi.org/10.1200/JCO.2023.41.16_suppl.e12607

Read next

See also:

Related medical questions

• How does carboplatin stop cancer?
• Does carboplatin cause neuropathy?
• What are monoclonal antibodies?
• What are biosimilar drugs and how do they compare to biologics?
• How long can you stay on Herceptin and Perjeta?
• What happens after Herceptin treatment?
• How long can I stay on Herceptin?
• What are the biosimilars of Herceptin?
• What are biologic drugs and how do they work?
• What biosimilars have been approved in the United States?
• What is Herceptin? Is Herceptin a chemo drug? How does it work?
• How long does Herceptin stay in your body?
• How do Herceptin (trastuzumab) and Perjeta (pertuzumab) work together?
• How effective is Herceptin for Breast & Gastric Cancer?
• What is the difference between Herceptin and Herceptin Hylecta?
• Does Herceptin (trastuzumab) stop menstrual periods?
• Do Herceptin (trastuzumab) injections hurt?
• What is the difference between Herzuma and Herceptin?
• What is the difference between Ogivri and Herceptin?
• How is Herceptin Injection and Herceptin Hylecta administered?

Drug information

• Taxotere (11 reviews)
• Carboplatin (5 reviews)
• Herceptin (12 reviews)
• Perjeta

Related support groups

• Taxotere (6 questions, 15 members)
• Carboplatin (7 questions, 14 members)
• Herceptin (21 questions, 32 members)
• Perjeta (8 questions, 6 members)
• Breast Cancer (130 questions, 311 members)

Medical Disclaimer